Xeris Biopharma stock (US98422E1038): earnings update and growth plans put focus on glucagon portfolio

Xeris Biopharma has recently reported quarterly figures and updated investors on its glucagon-based product portfolio and pipeline. The specialty pharma player, listed on Nasdaq, continues to push for scale in rare disease and endocrine markets.

Xeris Biopharma has remained in focus among healthcare investors after the specialty pharmaceutical company reported recent quarterly results and provided updates on its commercial portfolio built around its XeriSol and XeriJect formulation platforms. The company, listed on Nasdaq under the ticker XERS, highlighted ongoing revenue growth from its core glucagon product Gvoke and outlined plans to advance its pipeline, according to a results release published in early May 2025 on the company’s investor relations site Xeris investor relations as of 05/08/2025.

In that update for the first quarter of 2025, Xeris Biopharma reported total revenue of approximately 48 million USD for the period, compared with about 38 million USD in the same quarter a year earlier, reflecting continued uptake of its commercial products, according to the company’s Q1 2025 earnings press release dated May 8, 2025 Xeris press release as of 05/08/2025. Management also reiterated its focus on reaching sustainable cash flow breakeven through revenue growth and disciplined expense control.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Xeris Biopharma Holdings
• Sector/industry: Specialty pharmaceuticals / biotech
• Headquarters/country: Chicago, United States
• Core markets: Endocrinology, rare disease, hospital emergency medicine
• Key revenue drivers: Glucagon product Gvoke and related formulations
• Home exchange/listing venue: Nasdaq (ticker: XERS)
• Trading currency: USD

Xeris Biopharma: core business model

Xeris Biopharma focuses on developing and commercializing ready-to-use injectable and infusible formulations for endocrine and other specialty indications. The company’s technology platforms, branded as XeriSol and XeriJect, are designed to turn drugs that typically require reconstitution or refrigeration into more convenient liquid formulations that can be stored at room temperature, according to a description on its corporate website updated in 2025 Xeris corporate website as of 03/2025.

The business model combines in-house commercialization of proprietary endocrinology and emergency care medicines with potential partnerships for broader use of its formulation platforms. Xeris Biopharma currently markets products in the United States and selected international markets, with a primary focus on patients who require rapid and reliable glucagon administration for severe hypoglycemia and related metabolic emergencies, as highlighted in the company overview published alongside its annual report for 2024 on March 14, 2025 Xeris annual report materials as of 03/14/2025.

Unlike large diversified pharmaceutical companies, Xeris Biopharma remains a focused player that concentrates its research, development, and commercial infrastructure on a narrow set of therapeutic areas. Revenue is currently mainly derived from a few key products, while the pipeline aims to broaden its addressable market in the medium term. For investors, this concentration means that the performance of those flagship products, as well as the trajectory of the late-stage pipeline, have an outsized impact on the company’s overall financial results.

The company generates income primarily by selling finished pharmaceutical products rather than through licensing out intellectual property at this stage. However, its formulation technologies may enable collaborations in which partners bring active pharmaceutical ingredients while Xeris Biopharma provides delivery innovation. Such a model could create a mix of product sales, milestones, and potential royalties over time, though the current revenue base is still heavily skewed toward direct product sales according to management commentary in the Q1 2025 earnings materials Xeris earnings presentation as of 05/08/2025.

Main revenue and product drivers for Xeris Biopharma

The primary commercial asset for Xeris Biopharma is Gvoke, a ready-to-use liquid glucagon formulation for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. Gvoke is available as a prefilled syringe and an auto-injector format, designed to simplify administration during emergencies, according to prescribing information updated in 2024 on the company’s product page Xeris product information as of 11/2024. This product competes in a niche but essential segment where usability and reliability are critical, particularly for caregivers and non-medical responders.

Besides Gvoke, Xeris Biopharma has leveraged its formulation technology in ready-to-use glucagon for hospital and clinical settings, often marketed or partnered under different brand names depending on the region. These hospital-focused formulations aim to replace multi-step reconstitution kits traditionally used in emergency departments and inpatient units. The shift toward ready-to-use presentations can offer workflow advantages for healthcare providers, potentially improving adoption once hospital formularies are updated and staff become familiar with the new formats, as described in a case study released by the company in late 2024 Xeris news release as of 12/02/2024.

The company’s pipeline includes additional programs in endocrinology and related areas, where XeriSol and XeriJect could make existing therapies more convenient or open up new delivery routes. According to the pipeline snapshot included in the March 2025 corporate presentation, Xeris Biopharma is advancing candidates in areas such as obesity-related metabolic disorders and potential collaborations with larger pharmaceutical partners for biologic medicines Xeris corporate presentation as of 03/14/2025. These programs are generally earlier-stage and therefore carry higher development risk but could expand the company’s addressable markets significantly if successful.

From a financial perspective, recent quarterly updates suggest that product sales growth has been the main driver of top-line expansion. In the Q1 2025 release, management pointed to double-digit year-over-year growth in Gvoke prescriptions and continued penetration into both endocrinologist and primary care prescriber bases. The company also reported progress in international launches through distribution partners, although those markets currently contribute a smaller share of revenue than the United States, according to the same May 2025 update Xeris press release as of 05/08/2025.

On the cost side, Xeris Biopharma continues to invest in sales and marketing to support product uptake while also funding research and development for the next generation of formulations. The company indicated in its 2024 annual report that operating expenses remained elevated relative to revenue, resulting in a net loss for the year; however, the loss narrowed compared with 2023 as scale effects began to materialize Xeris annual report materials as of 03/14/2025. Management has communicated a goal of moving toward break-even through a combination of revenue growth and careful expense management, a typical trajectory for commercial-stage specialty pharma companies.

Conclusion

Xeris Biopharma has positioned itself as a focused player in the market for ready-to-use injectable therapies, with Gvoke and related glucagon products driving current revenue. Recent quarterly results show continued top-line growth and a gradual narrowing of losses, while the pipeline and formulation platforms provide potential for future expansion. At the same time, the company remains dependent on a relatively small product portfolio and continues to operate at a net loss, factors that contribute to volatility in the share price on Nasdaq and require ongoing access to capital markets. For US-based investors following the healthcare and biotech space, Xeris Biopharma represents a case study in how specialized formulation technologies can support a commercial-stage business, but also highlight the execution and regulatory risks inherent in the sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.